Therapy of paraneoplastic pemphigus with Rituximab: A case report and review of literature

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 1, 2006, Pages 69-74

  Barnadas, M A ^a   Roe, E ^a   Brunet, S ^a   Garcia, P ^a   Bergua, P ^a   Pimentel, L ^a   Puig, L ^a   Francia, A ^a   Garcia R ^a   Gelpi C ^a   Sierra, J ^a   Coll, P ^a   Alomar, A ^a  

^a Hospital Sta Creu i St Pau ^*  (Spain)

Author keywords

B cell lymphoma; Mycobacterium chelonae; Paraneoplastic pemphigus; Rituximab; Therapy

Indexed keywords

ACICLOVIR; AMPICILLIN; ANTIBIOTIC AGENT; CD20 ANTIGEN; CHLORAMBUCIL; CORTICOSTEROID; CYCLOSPORIN A; GENTAMICIN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VALACICLOVIR;

AGED; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECCHYMOSIS; ERYTHEMA MULTIFORME; FEMALE; FOLLICULAR LYMPHOMA; HEMATOMA; HERPES SIMPLEX VIRUS 1; HERPES VIRUS INFECTION; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; IMMUNOFLUORESCENCE TEST; LICHENOID ERUPTION; LISTERIA MONOCYTOGENES; MOUTH ULCER; MYCOBACTERIUM CHELONEI; MYOPATHY; NONHODGKIN LYMPHOMA; OSTEOPENIA; PARAKERATOSIS; PARANEOPLASTIC SYNDROME; PEMPHIGUS; PRIORITY JOURNAL; RASH; REVIEW; SEPSIS; SHORT COURSE THERAPY; SKIN ATROPHY; SKIN INFECTION; SKIN ULCER; SPINE INJURY; VARICELLA ZOSTER VIRUS;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FATAL OUTCOME; FEMALE; HUMANS; PARANEOPLASTIC SYNDROMES; PEMPHIGUS;

EID: 33645959854     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2005.01345.x     Document Type: Review

References (27)

1. Anhalt GJ, Kim SC, Stanley JR et al. Paraneoplastic pemphigus: An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729-1735.
2. Anhalt GJ. Paraneoplastic pemphigus. Adv Dermatol 1997; 1: 77-97.
3. MacLaughlin P, Grillo-López J, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Pathol 1998; 16: 2825-2833.
4. Maloney DG, Grillo-López A, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
5. Heizmann M, Itin P, Wernli M et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001; 66: 142-144.
6. Borradori L, Lombardi T, Samson J et al. Anti-CD20 monoclonal antibody (Rituximab) for refractory erosive stomatitis secondary to CD20+ follicular lymphoma associated paraneoplastic pemphigus. Arch Dermatol 2001; 137: 269-272.
7. Ahmed AR, Avram MM, Duncan LM. Case 23-2003: A 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions. N Engl J Med 2003; 349: 382-391.
8. Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol 2003; 2: 564-567.
9. Van Rossum MM, Verhaegen NTM, Jonkman MF et al. Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: Case report with review of novel treatment modalities. Leuk Lymphoma 2004; 45: 2327-2332.
10. Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol 1993; 129: 883-886.
11. Fullerton SH, Woodley DT, Smoller BR, Anhalt GJ. Paraneoplastic pemphigus with autoantibody deposition in bronchial epithelium after autologous bone marrow transplantation. J Am Med Assoc 1992; 267: 1500-1502.
12. Amagai M, Nishikawa T, Nousari H, Anhalt GJ. Hashimoto antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. Clin Invest 1998; 102: 775-782.
13. Reich K, Brinck U, Letschert M et al. Graft-versus-host disease like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus. Br J Dermatol 1999; 141: 739-746.
14. Kimyai-Asadi A, Jih MH. Paraneoplastic pemphigus. Int J Dermatol 2001; 40: 367-372.
15. Joly P, Richard C, Gilbert D et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 2000; 43: 619-626.
16. Wallace RJ Jr, Swenson JM, Silcox VA et al. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 1983; 5: 657-679.
17. Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: Importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than chlaritromycin. J Infect Dis 1992; 166: 405-412.
18. Perniciaro C, Kuechle MK, Colon-Otero G et al. Paraneoplastic pemphigus: a case of prolonged survival. Mayo Clin Proc 1994; 69: 851-855.
19. Hertzberg MS, Schifter M, Sullivan J, Stapleton K. Paraneoplastic pemphigus in two patients with B-cell non-Hodgkin's lymphoma: significant responses to cyclophosphamide and prednisolone. Am J Hematol 2000; 63: 105-106.
20. Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol 2000; 43: 1065-1069.
21. Williams JV, Marks JG Jr, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol 2000; 142: 506-508.
22. Zaja F, Russo D, Fuga G et al. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000; 55: 1062-1063.
23. Ratanatharathorn V, Carson E, Reynolds C et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000; 133: 275-279.
24. Shvidel L, Klepfish A, Berrebi A. Successful treatment with Rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin's lymphoma. Am J Hematol 2001; 67: 213-219.
25. Specks U, Fervenza FC, McDonald TJ, Hogan MCE. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44: 2836-2840.
26. Salopeck TG, Logsetty S, Tredger EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002; 47: 785-788.
27. España E, Fernández-Galar M, Lloret P et al. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 2004; 50: 974-976.